

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 109 to 115 of 2021**

Statements of Principles Nos. 109 to 115 of 2021 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 26 November 2021. The day of commencement as specified in each of these Instruments is 20 December 2021.

These Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on the Authority's website at http://www.rma.gov.au.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the Statement of Principles template which commenced in 2015. This document is also available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

8 December 2021

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REPEALS** | | | |
|  |  |  |  |
| 109 & 110/2021 | chronic solvent-induced neurocognitive disorder | 20/12/2021 | Nil |
|  |  |  |  |
| 111 & 112/2021 | motor neurone disease | 20/12/2021 | G12.2 |
|  |  |  |  |
| **DETERMINATIONS** | | | |
|  |  |  |  |
| 113 & 114/2021 | gender dysphoria | 20/12/2021 | Nil |
|  |  |  |  |
| **AMENDMENTS** | | | |
|  |  |  |  |
| 115/2021 | pilonidal sinus | 20/12/2021 | L05 |
|  |  |  |  |

Note:

1. The investigation concerning 'chronic solvent encephalopathy' has resulted in the determination of Statements of Principles concerning **chronic solvent-induced neurocognitive disorder**.
2. Following its focussed review in respect of prolonged sitting as a factor in pilonidal sinus, the Authority proposes to amend Statement of Principles No. 27 of 2019. The Authority does not propose to amend Statement of Principles No. 28 of 2019 and a Declaration is expected to appear in the Government Notices Gazette on 7 December 2021 advising of this outcome.

| **SUMMARY OF CHANGES** | | |
| --- | --- | --- |
| 109 & 110/2021 | chronic solvent-induced neurocognitive disorder | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 9 March 2021 concerning *chronic solvent encephalopathy* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 109/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the condition name from 'chronic solvent encephalopathy' to 'chronic solvent-induced neurocognitive disorder'; * new definition of 'chronic solvent-induced neurocognitive disorder' in subsection 7(2); * revising the factor in subsection 9(1) concerning having a severe substance use disorder involving inhalation of a solvent from the Specified List 1 of solvents, for clinical onset only; * revising the factor in subsection 9(2) concerning inhaling, ingesting or having cutaneous contact with a solvent from the Specified List 2 of solvents, for clinical onset only; * revising the factor in subsection 9(3) concerning having at least 50 episodes of acute solvent intoxication due to a solvent from the Specified List 2 of solvents, for clinical onset only; * new factor in subsection 9(4) concerning having an episode of acute solvent intoxication due to a solvent from the Specified List 3 of solvents, for clinical onset only; * new definitions of 'acute solvent intoxication', 'DSM-5', 'MRCA', 'Specified List 1 of solvents', 'Specified List 2 of solvents', 'Specified List 3 of solvents' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'relevant service' and 'severe substance use disorder' in Schedule 1 - Dictionary; and * deleting the definitions of 'acute volatile substance intoxication', 'an inhalant' and 'a volatile substance from the specified list'.   ***For BoP SoP (Instrument No. 110/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the condition name from 'chronic solvent encephalopathy' to 'chronic solvent-induced neurocognitive disorder'; * new definition of 'chronic solvent-induced neurocognitive disorder' in subsection 7(2); * revising the factor in subsection 9(1) concerning having a severe substance use disorder involving inhalation of a solvent from the Specified List 1 of solvents, for clinical onset only; * revising the factor in subsection 9(2) concerning inhaling, ingesting or having cutaneous contact with a solvent from the Specified List 2 of solvents, for clinical onset only; * revising the factor in subsection 9(3) concerning having at least 50 episodes of acute solvent intoxication due to a solvent from the Specified List 2 of solvents, for clinical onset only; * new factor in subsection 9(4) concerning having an episode of acute solvent intoxication due to a solvent from the Specified List 2 of solvents, for clinical onset only; * new definitions of 'acute solvent intoxication', 'DSM-5', 'MRCA', 'Specified List 1 of solvents', 'Specified List 2 of solvents' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'relevant service' and 'severe substance use disorder' in Schedule 1 - Dictionary; and * deleting the definitions of 'acute volatile substance intoxication', 'an inhalant' and 'a volatile substance from the specified list'.   **The determining of these Instruments finalises the investigation in relation to *chronic solvent encephalopathy* as advertised in the Government Notices Gazette of 9 March 2021.** |
| 111 & 112/2021 | motor neurone disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 5 January 2021 concerning *motor neurone disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 111/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'motor neurone disease' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset; * new factors in subsections 9(2) and 9(5) concerning being exposed to lead; * new factors in subsections 9(3) and 9(6) concerning inhaling formaldehyde; * new factor in subsection 9(4) concerning having smoked tobacco products, for clinical worsening; * new definitions of 'being exposed to lead as specified', 'lead process as specified', 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definition of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   ***For BoP SoP (Instrument No. 112/2021)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'motor neurone disease' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning having smoked tobacco products, for clinical onset; * new factor in subsection 9(2) concerning having smoked tobacco products, for clinical worsening; * new definitions of 'MRCA', 'one pack-year' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definition of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products'.   **The determining of these Instruments finalises the investigation in relation to *motor neurone disease* as advertised in the Government Notices Gazette of 5 January 2021.** |
| 113 & 114/2021 | gender dysphoria | **New Condition**  These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 6 July 2021 concerning *gender dysphoria* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence available to the Authority.  **The determining of these new Instruments finalises the investigation in relation to *gender dysphoria* as advertised in the Government Notices Gazette of 6 July 2021.** |
| 115/2021 | pilonidal sinus | **Amendment**  This instrument amends Statement of Principles No. 27 of 2019 concerning ***pilonidal sinus*** by:   * inserting new factors in paragraphs 9(2)(aa) and 9(5)(aa) concerning sitting on a hard or vibrating surface, for pilonidal sinus of the sacrococcygeal region only.   **The determining of this Instrument finalises the investigation in relation to *pilonidal sinus* as advertised in the Government Notices Gazette of 31 August 2021.** |